Adage Capital Partners Gp, L.L.C. Astria Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 875,000 shares of ATXS stock, worth $5.82 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
875,000
Previous 588,200
48.76%
Holding current value
$5.82 Million
Previous $3.14 Million
49.36%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding ATXS
# of Institutions
118Shares Held
51.7MCall Options Held
7KPut Options Held
6.1K-
Perceptive Advisors LLC New York, NY6.49MShares$43.1 Million1.53% of portfolio
-
Vestal Point Capital, LP New York, NY4.18MShares$27.8 Million1.59% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.11MShares$27.3 Million6.34% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$23.6 Million5.84% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$23.4 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $101M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...